Antipsychotic medications are the primary treatment for schizophrenia, but only 30% of patients are satisfied with their treatment during the first 18 months, and 20% to 30% experience...
Study Finds No Clear Advantage of CBT Over Other Therapies for Schizophrenia
Authors of this Cochrane Review assessed the effectiveness of cognitive behavioral therapy (CBT) compared to other psychosocial therapies when used...
Josh Hamilton,
DNP, APRN-BC, CTMH, CNE, CLNC, FAANP
Chief Clinical Officer, The Hamilton Group Behavioral Health LLC; Clinical Professor and Chair, College of Nursing, Washington State University
Researchers Investigate Relapse Risk and Predictors in Those With Schizophrenia Withdrawn From Treatment
This study quantified the risk and predictors of relapse among individuals with schizophrenia withdrawn from antipsychotic maintenance treatment....
Josh Hamilton,
DNP, APRN-BC, CTMH, CNE, CLNC, FAANP
Chief Clinical Officer, The Hamilton Group Behavioral Health LLC; Clinical Professor and Chair, College of Nursing, Washington State University
Intranasal Implants: Revolutionizing Schizophrenia Care With Targeted Delivery
The blood-brain barrier poses challenges for central nervous system (CNS) drug delivery, but intranasal administration offers a promising solution by...
Psychosocial Interventions Essential for Addressing Schizophrenia’s Negative Symptoms
Schizophrenia spectrum disorders (SSD) are severe mental health conditions marked by cognitive impairments, poor functional outcomes, reduced quality of life,...
Crystal Hopkins,
DNP, PMHNP-BC, FNP-BC
Founder and CEO, Better Mental Health and Consulting, LLC
